During a recent web presentation on its respiratory R&D activities, Teva announced that it plans to make 13 regulatory submissions for respiratory products over the next 5 years, introduce “proprietary devices addressing unmet needs,” and expand its respiratory business to become “a multi-billion $ franchise by the end of the decade.”
According to the company, its current billion-dollar respiratory products business ranks it as the 5th largest player in worldwide sales of respiratory drugs, with the majority of revenues coming from the Qvar and ProAir inhalers. Plans to strengthen the business include the introduction of new devices for those brands as well as entirely new inhalers.
The presentation promises a “deep dive” into its programs for DuoResp Spiromax, ProAir Spiromax, and FS Spiromax and notes that a 505(b)(2) submission is planned for ProAir Spiromax in mid-2014 and for FS Spiromax in 2015.
Teva’s recent acquisition of MicroDose Therapeutx has added MicroDose’s MDT-637 inhaled anti-viral for the treatment of RSV to its pipeline, and the company says that it plans to submit an NDA for the product in 2017.
View the Teva slide presentation.
